Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Anais brasileiros de dermatologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000400006 |
Resumo: | Abstract: Background: Actinic keratoses are benign intraepithelial skin neoplasms that develop in photoexposed areas and can progress to invasive carcinoma. They are seen frequently in dermatological practice, occurring in 5.1% of consultations. Ingenol mebutate (IM) was recently approved in Brazil as a topical therapy for field cancerization in actinic keratosis. Objective: To evaluate the clearance rate and adverse events in the treatment of actinic keratoses with ingenol mebutate. Methods: A longitudinal, prospective, non-randomized, interventional, open, single-center study was conducted. Patients with actinic keratoses applied ingenol mebutate on a 25cm2 area of the face and/or scalp for three consecutive days (0.015%) or on the forearm for two days (0.05%). Results: 27 patients completed the protocol, of whom 13 on the face and/or scalp and 14 on the forearm. Complete clearance occurred in 53.8% in the first group and 42.8% in the second. Partial response was observed in 15.4% and 35.7%, respectively. The most common side effects were erythema, edema, desquamation, pruritus, and local erosion. Study limitations: The study had a small sample and was not randomized, double-blind, placebo-controlled, or vehicle-controlled. Conclusion: Ingenol mebutate is well-tolerated for the treatment of actinic keratosis, with good patient adherence thanks to the short treatment period. |
id |
SBD-1_05e821aae962fa4d1bc5736927e5c105 |
---|---|
oai_identifier_str |
oai:scielo:S0365-05962018000400006 |
network_acronym_str |
SBD-1 |
network_name_str |
Anais brasileiros de dermatologia (Online) |
repository_id_str |
|
spelling |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effectsKeratosis, actinicSkin neoplasmsTherapeuticsTreatment outcomeAbstract: Background: Actinic keratoses are benign intraepithelial skin neoplasms that develop in photoexposed areas and can progress to invasive carcinoma. They are seen frequently in dermatological practice, occurring in 5.1% of consultations. Ingenol mebutate (IM) was recently approved in Brazil as a topical therapy for field cancerization in actinic keratosis. Objective: To evaluate the clearance rate and adverse events in the treatment of actinic keratoses with ingenol mebutate. Methods: A longitudinal, prospective, non-randomized, interventional, open, single-center study was conducted. Patients with actinic keratoses applied ingenol mebutate on a 25cm2 area of the face and/or scalp for three consecutive days (0.015%) or on the forearm for two days (0.05%). Results: 27 patients completed the protocol, of whom 13 on the face and/or scalp and 14 on the forearm. Complete clearance occurred in 53.8% in the first group and 42.8% in the second. Partial response was observed in 15.4% and 35.7%, respectively. The most common side effects were erythema, edema, desquamation, pruritus, and local erosion. Study limitations: The study had a small sample and was not randomized, double-blind, placebo-controlled, or vehicle-controlled. Conclusion: Ingenol mebutate is well-tolerated for the treatment of actinic keratosis, with good patient adherence thanks to the short treatment period.Sociedade Brasileira de Dermatologia2018-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000400006Anais Brasileiros de Dermatologia v.93 n.4 2018reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20186982info:eu-repo/semantics/openAccessSaraiva,Maria Isabel RamosPortocarrero,Larissa Karine LeiteVieira,Marcella Amaral Horta BarbosaSwiczar,Bethania Cabral CavalliWestin,Andrezza Telleseng2018-07-26T00:00:00Zoai:scielo:S0365-05962018000400006Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2018-07-26T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false |
dc.title.none.fl_str_mv |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects |
title |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects |
spellingShingle |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects Saraiva,Maria Isabel Ramos Keratosis, actinic Skin neoplasms Therapeutics Treatment outcome |
title_short |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects |
title_full |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects |
title_fullStr |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects |
title_full_unstemmed |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects |
title_sort |
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects |
author |
Saraiva,Maria Isabel Ramos |
author_facet |
Saraiva,Maria Isabel Ramos Portocarrero,Larissa Karine Leite Vieira,Marcella Amaral Horta Barbosa Swiczar,Bethania Cabral Cavalli Westin,Andrezza Telles |
author_role |
author |
author2 |
Portocarrero,Larissa Karine Leite Vieira,Marcella Amaral Horta Barbosa Swiczar,Bethania Cabral Cavalli Westin,Andrezza Telles |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Saraiva,Maria Isabel Ramos Portocarrero,Larissa Karine Leite Vieira,Marcella Amaral Horta Barbosa Swiczar,Bethania Cabral Cavalli Westin,Andrezza Telles |
dc.subject.por.fl_str_mv |
Keratosis, actinic Skin neoplasms Therapeutics Treatment outcome |
topic |
Keratosis, actinic Skin neoplasms Therapeutics Treatment outcome |
description |
Abstract: Background: Actinic keratoses are benign intraepithelial skin neoplasms that develop in photoexposed areas and can progress to invasive carcinoma. They are seen frequently in dermatological practice, occurring in 5.1% of consultations. Ingenol mebutate (IM) was recently approved in Brazil as a topical therapy for field cancerization in actinic keratosis. Objective: To evaluate the clearance rate and adverse events in the treatment of actinic keratoses with ingenol mebutate. Methods: A longitudinal, prospective, non-randomized, interventional, open, single-center study was conducted. Patients with actinic keratoses applied ingenol mebutate on a 25cm2 area of the face and/or scalp for three consecutive days (0.015%) or on the forearm for two days (0.05%). Results: 27 patients completed the protocol, of whom 13 on the face and/or scalp and 14 on the forearm. Complete clearance occurred in 53.8% in the first group and 42.8% in the second. Partial response was observed in 15.4% and 35.7%, respectively. The most common side effects were erythema, edema, desquamation, pruritus, and local erosion. Study limitations: The study had a small sample and was not randomized, double-blind, placebo-controlled, or vehicle-controlled. Conclusion: Ingenol mebutate is well-tolerated for the treatment of actinic keratosis, with good patient adherence thanks to the short treatment period. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-08-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000400006 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000400006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/abd1806-4841.20186982 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
dc.source.none.fl_str_mv |
Anais Brasileiros de Dermatologia v.93 n.4 2018 reponame:Anais brasileiros de dermatologia (Online) instname:Sociedade Brasileira de Dermatologia (SBD) instacron:SBD |
instname_str |
Sociedade Brasileira de Dermatologia (SBD) |
instacron_str |
SBD |
institution |
SBD |
reponame_str |
Anais brasileiros de dermatologia (Online) |
collection |
Anais brasileiros de dermatologia (Online) |
repository.name.fl_str_mv |
Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD) |
repository.mail.fl_str_mv |
abd@sbd.org.br||revista@sbd.org.br |
_version_ |
1752126422952968192 |